ALC vs EW

For growth investors, Edwards Lifesciences Corporation (EW) is the stronger pick with 11.

5% revenue growth year-over-year, versus 4. 9% for Alcon Inc. (ALC). Alcon Inc. (ALC) offers the better valuation at 31. 6x trailing P/E (18. 1x forward), making it the more compelling value choice. Analysts rate Alcon Inc. (ALC) a "Buy" — based on 26 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Alcon Inc.

(ALC) is the cheapest at 31. 6x versus Edwards Lifesciences Corporation at 43. 7x. On forward P/E, Alcon Inc. is actually cheaper at 18. 1x.

Over the past 5 years, Alcon Inc.

(ALC) delivered a total return of -5. 7%, compared to -11. 5% for Edwards Lifesciences Corporation (EW). Over 10 years, the gap is even starker: EW returned +125. 5% versus ALC's +11. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Edwards Lifesciences Corporation (EW) is the lower-risk stock at 0.

64β versus Alcon Inc. 's 0. 68β — meaning ALC is approximately 7% more volatile than EW relative to the S&P 500. On balance sheet safety, Edwards Lifesciences Corporation (EW) carries a lower debt/equity ratio of 7% versus 24% for Alcon Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Edwards Lifesciences Corporation (EW) is pulling ahead at 11.

5% versus 4. 9% for Alcon Inc. (ALC). On earnings-per-share growth, the picture is similar: Alcon Inc. grew EPS -3. 4% year-over-year, compared to -73. 7% for Edwards Lifesciences Corporation. Over a 3-year CAGR, ALC leads at 6. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Edwards Lifesciences Corporation (EW) is the more profitable company, earning 17.

7% net margin versus 9. 4% for Alcon Inc. — meaning it keeps 17. 7% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: EW leads at 27. 0% versus 13. 1% for ALC. At the gross margin level — before operating expenses — EW leads at 78. 1%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Alcon Inc.

(ALC) trades at 18. 1x forward P/E versus 26. 6x for Edwards Lifesciences Corporation — 8. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for ALC: 38. 3% to $86. 52.

In this comparison, ALC (0.

5% yield) pays a dividend. EW does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Alcon Inc.

(ALC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 68), 0. 5% yield). Both have compounded well over 10 years (ALC: +11. 4%, EW: +125. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

ALC pays a dividend while EW does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.